[The treatment of HIV infection].
The combination of zidovudine (AZT) + lamivudine (3TC) twice a day + tenofovir once a day, in HIV-infected, antiretroviral-naive patients leads to the rapid and prolonged reduction in viral load, with good immune response and reasonable tolerance profile. According to the results of the boosted FosAmprenavir solo trial, adherence was simplified by the reduced number of daily administration and tablets (once a day) and hence a decline in virological failure rates. Enfuvirtide, an antiretroviral inhibiting the fusion of the virus membrane and cell, combined with optimal antiviral therapy, leads to virological response in 78% of patients and prolonged for more than 6 months in 33%, with good tolerance. In patients treated with neviparine, the frequency of hepatotoxicity justifies early and rigorous monitoring of the hepatic enzymes, notably in the case of high transaminase levels before initiation of treatment.
Girault
Véronique
V
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D002219:Carbamates; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D019829:Nevirapine / Q000009:adverse effects; D010755:Organophosphates / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use; D000068698:Tenofovir; D015215:Zidovudine / Q000627:therapeutic use
D044966:Anti-Retroviral Agents; D002219:Carbamates; D005663:Furans; D010755:Organophosphates; D063065:Organophosphonates; D013449:Sulfonamides; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine; D000068698:Tenofovir; D000225:Adenine; C426859:fosamprenavir